References
- Gerties M, Edgman-Levitan S, Daley J, Delbanco T. Through the patient’s eyes. Jossey-Bass, Inc., San Francisco, CA, USA, 1999
- Awad AG, Voruganti LNP. Impact of atypical antipsychotic on quality of life in patients with schizophrenia. CNS Drugs 2004;18:877-93
- Awad AG, Voruganti LNP. The impact of the newer antipsychotics on patient-reported outcomes in schizophrenia. CNS Drugs 2013;27:625-36
- US FDA Guidance for industry. Patient-reported outcomes measure: use in medical product development to support labelling claims. Health Qual Life Outcomes 2006;4:79
- Voruganti LNP, Heselgrave RS, Awad AG, et al. Quality of life measurement in schizophrenia: reconciling the question of subjectivity with quest of reliability. Psychol Med 1998;28:165-72
- Awad AG, Voruganti LNP. The subjective/objective dichotomy: relevance to nosology, research and management. In: Gaebel W, editor. Zukunfts Perspectives in Psychiatries and Psychotherapie. Steinkopff Verlag; Darmstadt: 2002. p. 21-7
- Wehmeier PM, Kluge M, Schact A, et al. Correlation of physician and patient-related quality of life during antipsychotic treatment in outpatients with schizophrenia. Schizophr Res 2007;91:178-86
- Awad AG. Subjective tolerability of antipsychotic medications and the emerging science of subjective tolerability disorders. Expert Rev Pharmacoecon Outcomes Res 2010;10:1-4
- Voruganti LNP, Awad AG. Subjective and behavioural consequences of striatal dopamine depletion in schizophrenia: findings from in vivo SPECT study. Schizophr Res 2006;88:179-86
- De Haan L, Lavalaye J, Linszend D, et al. Subjective experience and striatal dopamine D2 receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. Am J Psychiatry 2000;157:1019-20
- Mizrahi R, Mamo D, Pausion P, et al. The relationship between subjective well-being and dopamine D2 receptors and a full antagonist antipsychotic. Int J Neuropsychopharmacology 2009;5:715-21
- Awad AG, Voruganti LNP. Measuring quality of life in patients with schizophrenia – an update. Pharmacoeconomics 2012;30:183-95
- Awad AG. Antipsychotics medication: how satisfied are our patients? Clear Perspective. Management issues in schizophrenia 1999;2:1-6
- Brissos S, Molodynski A, Dias V, et al. The importance of measuring social functioning in schizophrenia. Ann Gen Psychiatry 2011;10:1-7
- ISPOR Good practices for outcomes research; International society for pharmacoeconomics and outcomes research. 2013. Available from: www.ISPOR@[email protected]
- Cella D, Yount S, Rothrock N, et al. The Patient-reported outcomes measurement information system (PROMIS): Progress of a NIH roadmap cooperative group doing its first two years. Med Care 2007;45:S3-S11
- Patient-centred care: improving quality of life and safety by focusing care on patients and consumers. Submission to the Australian commission on safety and quality in healthcare – Discussion paper submitted by the Royal Australian & New Zealand College of Physicians. 2010. Available from: www.ranzcp.org